Article:Latent viruses can cause disease by disrupting the competition for the limiting factor p300/CBP (6260892)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Latent viruses can cause disease by disrupting the competition for the limiting factor p300/CBP and the publication date was 2018-11-26. The initial author is Hanan Polansky.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Cellular & Molecular Biology Letters

Latent viruses can cause disease by disrupting the competition for the limiting factor p300/CBP

  • Hanan Polansky
  • Hava Schwab

Publication date (epub): 11/2018

Publication date (pmc-release): 11/2018

Publication date (collection): /2018


CBP and p300 are histone acetyltransferase coactivators that control the transcription of numerous genes in humans, viruses, and other organisms. Although two separate genes encode CBP and p300, they share a 61% sequence identity, and they are often mentioned together as p300/CBP. Zhou et al. showed that under hypoxic conditions, HIF1α and the tumor suppressor p53 compete for binding to the limiting p300/CBP coactivator. Jethanandani & Kramer showed that δEF1 and MYOD genes compete for the limited amount of p300/CBP in the cell. Bhattacharyya et al. showed that the limiting availability of p300/CBP in the cell serves as a checkpoint for HIF1α activity. Here, we use the microcompetition model to explain how latent viruses with a specific viral cis-regulatory element in their promoter/enhancer can disrupt this competition, causing diseases such as cancer, diabetes, atherosclerosis, and obesity.


With at least 315 different cellular and viral interacting proteins, CBP and p300 are considered the most heavily connected coactivators in the mammalian protein–protein interaction network [[1], [2]]. Both are histone acetyltransferases, and they control the transcription of numerous genes in humans, viruses, and other organisms. Although two separate genes encode CBP and p300, they share a 61% sequence identity, and they are often mentioned together as p300/CBP [[3]].

p300/CBP is a 300-kDa protein that has a CH2 domain, which contains its acetyltransferase activity, and five protein-binding domains [[3]]. Many studies have shown that competition for the limiting p300/CBP is an important mechanism that regulates transcription and cellular activities. This commentary discusses three of these studies [[4][6]] and connects their observations to the microcompetition model [[7], [8]].

Using differential equations and a dimensionless state variable, Zhou et al. [[5]] determined the effect of p300 on the steady-state concentrations of proteins. They discovered that under hypoxic conditions, HIF1α and the tumor suppressor p53 compete for binding to the coactivator p300. They showed that p300 is required for full transcriptional activity of both p53 and HIF1α. According to Zhou et al., this competition indicates that p300 is limiting.

The α7 integrin is involved in the differentiation of myoblasts and is negatively regulated by δEF1, a zinc finger transcription factor, and positively regulated by MYOD. δEF1 has an NR (negative region) domain that binds the p300/CBP coactivator. Overexpression of δEF1 inhibits muscle cell differentiation and represses the activation of the muscle creatine kinase enhancer. On the other hand, MYOD activates muscle genes by binding p300, and uses p300/CBP histone acetylase activity to allow for transcription [[4]].

Jethanandani & Kramer [[4]] transfected C2C12 cells with the p400 fragment of the α7 integrin promoter. Then, they co-transfected the cells with either δEF1 alone, δEF1 and MYOD, or δEF1 and CBP, and measured the CAT reporter activity. They observed that CBP increased CAT activity, i.e., an increase in CBP levels mitigated the repression of α7 by δEF1. Based on their results, Jethanandani & Kramer concluded that p300/CBP is limiting, and that δEF1 competes with MYOD for the limited amounts of p300/CBP in the cell.

Bhattacharyya et al. [[6]] infected human gastric epithelium cells with Helicobacter pylori. The results showed an increase in transcription complex formation at the HREs (hypoxia-response elements) of the mcl1 promoter. Then, they observed that the complex included p300, HIF1α, and APE1 (apurinic/apyrimidinic endonuclease 1). Western blotting on whole cell lysates from AGS cells showed that the binding of p300 to the hif1α promoter decreased at higher levels of H. pylori infection, without a decrease in the p300 concentration. Moreover, they found that higher levels of H. pylori infection increased the expression of hif1α, but decreased the expression of the mcl1 promoter, which is transactivated by HIFα. They discovered that at higher H. pylori levels, HIF1α binds to the HIF-binding site (HBS) on the hif1α promoter. Since the HBS is transcriptionally inactive (it lacks the required HIF ancillary sequence, denoted as HAS), this binding does not further transactivate the hif1α promoter. However, this binding has a sequestering effect that limits the intracellular availability of the HIF1α•p300 complex to the mcl1 gene, which decreases mcl1 expression.

The observations in the Bhattacharyya et al. study indicate that p300 is limiting, meaning the HIF1α•p300 complex is limiting. They also show that the decrease in HIF1α•p300 binding to the mcl1 promoter, which decreases mcl1 transcription, is due to competition for the limiting HIF1α•p300 by the hif1α promoter itself. Based on their observations, Bhattacharyya et al. concluded that the limiting availability of p300 in the cell is a checkpoint for HIF1α activity.

These studies showed that competition between cellular transcription factors to bind the limiting p300/CBP is an important regulator of transcription. According to the microcompetition model, disrupting this regulation causes many diseases. The microcompetition model was first described in the book Microcompetition with Foreign DNA and the Origin of Chronic Disease [[7], [8]]. It centers on one type of disruption of this regulation: the one caused by the viruses with an N-box, which is a strong cis-regulatory element found on their promoters/enhancers. During the latent phase, this element binds the cellular GABP•p300/CBP transcription complex, which is limiting, because p300/CBP is limiting. Therefore, the viral N-boxes decrease the availability of GABP•p300/CBP in the cell. The result is abnormal expression of the cellular genes that bind GABP•p300/CBP. The genes that are transactivated by the GABP•p300/CBP complex synthesize fewer proteins, while those that are transrepressed by the complex synthesize more proteins. The abnormal levels of these cellular proteins can cause disease, such as cancer, diabetes, atherosclerosis, and obesity. The book lists human genes that bind the GABP•p300/CBP complex (Table 1) and presents supporting evidence to show that these genes express abnormal levels of their proteins in these diseases.Table 1

List of some human genes that bind the GABP•p300/CBP transcription complex

Gene Reference
β2 leukocyte integrin (CD18) Rosmarin et al. 1998 [[22]]
Interleukin 16 (IL-16) Bannert et al. 1999 [[23]]
Interleukin 2 (IL-2) Avots et al. 1997 [[24]]
Interleukin 2 receptor β-chain (IL-2Rβ) Lin et al. 1993 [[25]]
IL-2 receptor γ-chain (IL-2 γc) Markiewicz et al. 1996 [[26]]
Human secretory interleukin-1 receptor antagonist (secretory IL-1ra) Smith et al. 1998 [[27]]
Retinoblastoma (Rb) Sowa et al. 1997 [[28]]
Human thrombopoietin (TPO) Kamura et al. 1997 [[29]]
Aldose reductase Wang et al. 1993 [[30]]
Neutrophil elastase (NE) Nuchprayoon et al. 1999 [[31]], Nuchprayoon et al. 1997 [[32]]
Folate binding protein (FBP) Sadasivan et al. 1994 [[33]]
Cytochrome c oxidase subunit Vb (COXVb) Basu et al. 1993 [[34]], Sucharov et al. 1995 [[35]]
Cytochrome c oxidase subunit IV Carter et al. 1994 [[36]], Carter et al. 1992 [[37]]
Mitochondrial transcription factor A (mtTFA) Virbasius et al. 1994 [[38]]
β subunit of the FoF1 ATP synthase (ATPsynβ) Villena et al. 1998 [[39]]
Prolactin (PRL) Ouyang et al. 1996 [[40]]
Oxytocin receptor (OTR) Hoare et al. 1999 [[41]]

Some common viruses with an N-box are the cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1 (HSV-1), human T-cell lymphotropic virus (HTLV), and human immunodeficiency virus (HIV). These viruses are highly prevalent. For instance, an estimated 3.7 billion people worldwide, or around 67% of the global population, are infected with HSV-1 [[9]]. Since the virus is highly prevalent, why do only a fraction of infected people develop the disease? The answer is that the copy number during latency matters. Only a high enough copy number produces the strong enough sequestering effect that causes a disease (Fig. 1).Fig. 1

Latent viruses, the microcompetition model, and disease. a Immunodeficiency occurs due to stress, aging, disease, etc. b More copies of the latent virus are present in the system c Due to the increase in the copies of latent viruses, more GABP•p300/CBP complexes bind the viral promoters. d As a result, fewer GABP•p300/CBP complexes are available to bind the promoter of the cellular gene. e A lower or higher expression of cellular genes. f Disease occurs

A recent paper by Zuo et al. [[10]] showed that the copy number of latent EBV, a virus that binds GABP•p300/CBP during latency, is strongly associated with oncogenicity [[11], [12]]. What determines the copy number of a virus during its latent phase? It is well known that there is a balance between the efficiency of the immune system and the copy number of latent viruses. It is also known that many events can cause immunodeficiency, including aging [[13]], certain medications [[14], [15]], surgery [[16][18]], chemotherapy [[19]], radiation [[20]], and stress [[21]]. Such events decrease the efficiency of the immune system, increasing the copy number of latent viruses and the risk of disease, as observed by Zuo et al., who stated:

“It has been noticed that EBV load in tumor tissues or blood is associated with the clinical progression and prognosis in both lymphoma and NPC. Our result verifies this association. We also emphasize the importance to measure the level of gene expression or copy number in the virus study instead of only concerning ‘with and without’.”

Our interpretation of the microcompetition model agrees with that of Zuo et al. It is the copy number of the viruses that sequester the limiting GABP•p300/CBP transcription complex and not the ‘infected or not infected’ that determines the fate of the infected individual. Therefore, it should be measured in clinical practice.

To conclude, the microcompetition model explains how an increase in the copy number of a latent virus that binds the limiting GABP•p300/CBP transcription complex increases the sequestering of the complex. This disrupts the allocation of the complex to cellular genes that compete to bind the complex. When this disruption is large enough, the host develops a disease.



Not applicable


The authors have no funding to declare.

Availability of data and materials

Not applicable


  1. J RualK VenkatesanT HaoTowards a proteome-scale map of the human protein–protein interaction networkNature200543770621173117810.1038/nature0420916189514
  2. L KasperT FukuyamaM BiesenConditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell developmentMol Cell Biol200626378980910.1128/mcb.26.3.789-809.200616428436
  3. L KasperP BrindleMammalian gene expression program resiliency: the roles of multiple coactivator mechanisms in hypoxia–responsive transcriptionCell Cycle20055214214610.4161/cc.5.2.2353
  4. P JethanandaniR Kramerα7 integrin expression is negatively regulated by δEF1 during skeletal MyogenesisJ Biol Chem200528043360373604610.1074/jbc.m50869820016129691
  5. Zhou C, Zhang X, Liu F, Wang W. Modeling the interplay between the HIF-1 and p53 pathways in hypoxia. Sci Rep. 2015;5(1). 10.1038/srep13834.
  6. A BhattacharyyaR ChattopadhyayE HallS MebrahtuP ErnstS CroweMechanism of hypoxia-inducible factor 1α-mediated Mcl1 regulation in helicobacter pylori-infected human gastric epitheliumAm J Physiol Gastrointest Liver Physiol20102995G1177G118610.1152/ajpgi.00372.201020829524
  7. H PolanskyMicrocompetition with Foreign DNA and the Origin of Chronic Disease2003Rochester, NYCBCD Publishing
  8. Polansky H, Javaherian A. 3-Econsystems: MicroRNAs, receptors, and latent viruses; some insights biology can gain from economic theory. Front Microbiol. 2016;7:369. 10.3389/fmicb.2016.00369.
  9. Herpes simplex virus. World Health Organization. Published 2018. Accessed August 27, 2018.
  10. L ZuoH YuL LiuThe copy number of Epstein-Barr virus latent genome correlates with the oncogenicity by the activation level of LMP1 and NF-κBOncotarget2015638410334104410.18632/oncotarget.570826517512
  11. Polansky H, Schwab H. Copy number of latent viruses, oncogenicity, and the microcompetition model. Oncotarget. 2018;9(60). 10.18632/oncotarget.25804.
  12. Zuo L, Du S, Liu L, Lu J. The oncogenicity of Epstein-Barr virus: being “more or less” is to be concerned. Can Cell Microenviron. 2016;3:e1300. 10.14800/ccm.1300.
  13. C Castelo-BrancoI SoveralThe immune system and aging: a reviewGynecol Endocrinol201430162210.3109/09513590.2013.85253124219599
  14. Ettore BeghiSimon ShorvonAntiepileptic drugs and the immune systemEpilepsia201152404410.1111/j.1528-1167.2011.03035.x21542845
  15. R RøgeBK MøllerCR AndersenCU CorrellJ NielsenImmunomodulatory effects of clozapine and their clinical implications: what have we learned so far?Schizophr Res201214020421310.1016/j.schres.2012.06.02022831769
  16. Dorothee DeckerRene TolbaWolfram SpringerHolger LauschkeAndreas HirnerAlexander von RueckerAbdominal Surgical Interventions: Local and Systemic Consequences for the Immune System—a Prospective Study on Elective Gastrointestinal Surgery1Journal of Surgical Research20051261121810.1016/j.jss.2005.01.00615916969
  17. Brøchner AC, Mikkelsen S, Hegelund I, Hokland M, Mogensen O, Toft P. The immune response is affected for at least three weeks after extensive surgery for ovarian cancer. Dan Med J. 2016;63.
  18. Leonard AngkaSarwat KhanMarisa KilgourRebecca XuMichael KennedyRebecca AuerDysfunctional Natural Killer Cells in the Aftermath of Cancer SurgeryInternational Journal of Molecular Sciences2017188178710.3390/ijms18081787
  19. F GhiringhelliL ApetohThe interplay between the immune system and chemotherapy: emerging methods for optimizing therapyExpert Rev Clin Immunol201410193010.1586/1744666X.2014.86552024308838
  20. US GaiplModulation of the immune system by ionizing irradiation and chemotherapeutic agents - contribution of immune activation and blocking of immune suppression to cancer therapy successCurr Med Chem2012191739174010.2174/09298671280009975822414098
  21. A VitlicJM LordAC PhillipsStress, ageing and their influence on functional, cellular and molecular aspects of the immune systemAge (Dordr)201436963110.1007/s11357-014-9631-624562499
  22. AG RosmarinM LuoDG CaprioJ ShangCP SimkevichSp1 cooperates with the ets transcription factor, GABP, to activate the CD18 (beta2 leukocyte integrin) promoterJ Biol Chem1998273130971310310.1074/jbc.273.21.130979582348
  23. R BannertA AvotsM BaierE SerflingR KurthGA-binding protein factors, in concert with the coactivator CREB binding protein/p300, control the induction of the interleukin 16 promoter in T lymphocytesProc Natl Acad Sci U S A1999961541154610.1073/pnas.96.4.15419990060
  24. A AvotsA HoffmeyerE FloryA CimanisUR RappE SerflingGABP factors bind to a distal interleukin 2 (IL-2) enhancer and contribute to c-Rafmediated increase in IL-2 inductionMol Cell Biol1997174381438910.1128/MCB.17.8.43819234696
  25. JX LinNK BhatS JohnWS QuealeWJ LeonardCharacterization of the human interleukin-2 receptor beta-chain gene promoter: regulation of promoter activity by ets gene productsMol Cell Biol1993136201621010.1128/MCB.13.10.62018413220
  26. S MarkiewiczR BosselutF Le DeistJP de VillartayC HivrozJ GhysdaelA FischerG de Saint BasileTissue-specific activity of the gammac chain gene promoter depends upon an Ets binding site and is regulated by GA-binding proteinJ Biol Chem1996271148491485510.1074/jbc.271.25.148498663060
  27. MF Smith JrVS CarlT LodieMJ FentonSecretory interleukin-1 receptor antagonist gene expression requires both a PU.1 and a novel composite NF-kappaB/PU.1/ GA-binding protein binding siteJ Biol Chem1998273242722427910.1074/jbc.273.37.242729727052
  28. Y SowaY ShiioT FujitaT MatsumotoY OkuyamaD KatoJ InoueJ SawadaM GotoH WatanabeH HandaT SakaiRetinoblastoma binding factor 1 site in the core promoter region of the human RB gene is activated by hGABP/E4TF1Cancer Res199757314531489242441
  29. T KamuraH HandaN HamasakiS KitajimaCharacterization of the human thrombopoietin gene promoter. A possible role of an Ets transcription factor, E4TF1/GABPJ Biol Chem199727217113611136810.1074/jbc.272.17.113619111044
  30. K WangKM BohrenKH GabbayCharacterization of the human aldose reductase gene promoterJ Biol Chem199326816052160588340427
  31. I NuchprayoonJ ShangCP SimkevichM LuoAG RosmarinAD FriedmanAn enhancer located between the neutrophil elastase and proteinase 3 promoters is activated by Sp1 and an Ets factorJ Biol Chem19992741085109110.1074/jbc.274.2.10859873055
  32. I NuchprayoonCP SimkevichM LuoAD FriedmanRosmarin AG. GABP cooperates with c-Myb and C/EBP to activate the neutrophil elastase promoterBlood199789454645549192779
  33. E SadasivanMM CedenoSP RothenbergCharacterization of the gene encoding a folate-binding protein expressed in human placenta. Identification of promoter activity in a G-rich SP1 site linked with the tandemly repeated GGAAG motif for the ets encoded GA-binding proteinJ Biol Chem1994269472547358106441
  34. A BasuK ParkML AtchisonRS CarterNG AvadhaniIdentification of a transcriptional initiator element in the cytochrome c oxidase subunit Vb promoter which binds to transcription factors NF-E1 (YY-1, delta) and Sp1J Biol Chem1993268418841968382696
  35. C SucharovA BasuRS CarterAvadhani NG. A novel transcriptional initiator activity of the GABP factor binding ets sequence repeat from the murine cytochrome c oxidase Vb geneGene Expr19955931118821623
  36. RS CarterNG AvadhaniCooperative binding of GA-binding protein transcription factors to duplicated transcription initiation region repeats of the cytochrome c oxidase subunit IV geneJ Biol Chem1994269438143878308008
  37. RS CarterNK BhatA BasuNG AvadhaniThe basal promoter elements of murine cytochrome c oxidase subunit IV gene consist of tandemly duplicated ets motifs that bind to GABP-related transcription factorsJ Biol Chem199226723418234261331086
  38. JV VirbasiusRC ScarpullaActivation of the human mitochondrial transcription factor a gene by nuclear respiratory factors: a potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesisProc Natl Acad Sci U S A1994911309131310.1073/pnas.91.4.13098108407
  39. JA VillenaO VinasT MampelR IglesiasM GiraltF VillarroyaRegulation of mitochondrial biogenesis in brown adipose tissue: nuclear respiratory factor-2/GA-binding protein is responsible for the transcriptional regulation of the gene for the mitochondrial ATP synthase beta subunitBiochem J199833112112710.1042/bj33101219512469
  40. L OuyangKK JacobFM StanleyGABP mediates insulin-increased prolactin gene transcriptionJ Biol Chem1996271104251042810.1074/jbc.271.18.104258631833
  41. S HoareJA CoplandTG WoodYJ JengMG IzbanMS SoloffIdentification of a GABP alpha/beta binding site involved in the induction of oxytocin receptor gene expression in human breast cells, potentiation by c-Fos/c-JunEndocrinology19991402268227910.1210/endo.140.5.671010218980
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as viral infectious disease.